CL2017003295A1 - Anticuerpos contra csf-1r humano para su uso en la inducción de linfocitosis en linfomas o leucemias - Google Patents
Anticuerpos contra csf-1r humano para su uso en la inducción de linfocitosis en linfomas o leucemiasInfo
- Publication number
- CL2017003295A1 CL2017003295A1 CL2017003295A CL2017003295A CL2017003295A1 CL 2017003295 A1 CL2017003295 A1 CL 2017003295A1 CL 2017003295 A CL2017003295 A CL 2017003295A CL 2017003295 A CL2017003295 A CL 2017003295A CL 2017003295 A1 CL2017003295 A1 CL 2017003295A1
- Authority
- CL
- Chile
- Prior art keywords
- lymphocytosis
- leukemias
- lymphomas
- induction
- antibodies against
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN SE REFIERE A LA LINFOCITOSIS INDUCIDA POR ANTI-CSF-1R EN LINFOMAS Y LEUCEMIAS Y A UNA TERAPIA COMBINADA DE ANTICUERPOS QUE SE UNEN A CSF-1R HUMANO CON ANTICUERPOS QUE SE UNEN A CD20 HUMANO.</p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15173638.6A EP3108897A1 (en) | 2015-06-24 | 2015-06-24 | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
EP16151129 | 2016-01-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2017003295A1 true CL2017003295A1 (es) | 2018-06-01 |
Family
ID=56263686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2017003295A CL2017003295A1 (es) | 2015-06-24 | 2017-12-21 | Anticuerpos contra csf-1r humano para su uso en la inducción de linfocitosis en linfomas o leucemias |
Country Status (17)
Country | Link |
---|---|
US (1) | US20180222985A1 (es) |
EP (1) | EP3313442B1 (es) |
JP (1) | JP6811733B2 (es) |
KR (1) | KR20180012873A (es) |
CN (1) | CN107847592B (es) |
AU (1) | AU2016282877A1 (es) |
BR (1) | BR112017027614A2 (es) |
CA (1) | CA2987716A1 (es) |
CL (1) | CL2017003295A1 (es) |
CR (1) | CR20170537A (es) |
HK (1) | HK1252860A1 (es) |
IL (1) | IL256135A (es) |
MX (1) | MX2017016651A (es) |
PE (1) | PE20181050A1 (es) |
RU (1) | RU2018102575A (es) |
WO (1) | WO2016207312A1 (es) |
ZA (1) | ZA201708074B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109475603B (zh) | 2016-06-20 | 2023-06-13 | 科马布有限公司 | 抗pd-l1抗体 |
EA201992311A1 (ru) | 2017-04-01 | 2020-05-15 | Бэйцзин Ханми Фарм. Ко., Лтд. | Гетеродимерное биспецифичное антитело к pd-l1/pd-1 со структурой, подобной натуральному антителу, и его получение |
JP2020517256A (ja) | 2017-04-19 | 2020-06-18 | エルスター セラピューティクス, インコーポレイテッド | 多重特異性分子およびその使用 |
CN111032692A (zh) | 2017-08-08 | 2020-04-17 | 豪夫迈·罗氏有限公司 | 一种dlbcl患者亚组的奥滨尤妥珠单抗治疗 |
WO2019113464A1 (en) | 2017-12-08 | 2019-06-13 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
CN109053888B (zh) * | 2018-07-18 | 2020-06-19 | 博奥信生物技术(南京)有限公司 | 一种抗人csf-1r单克隆抗体及其用途 |
CN109053886B (zh) * | 2018-07-18 | 2020-07-28 | 博奥信生物技术(南京)有限公司 | 抗人csf-1r单克隆抗体及用途 |
CN113164777A (zh) | 2018-09-27 | 2021-07-23 | 马伦戈治疗公司 | Csf1r/ccr2多特异性抗体 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE038955T2 (hu) * | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval |
CN101291954B (zh) * | 2005-08-26 | 2013-03-27 | 罗氏格黎卡特股份公司 | 具有改变的细胞信号传导活性的修饰的抗原结合分子 |
ES2722300T3 (es) * | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
AR080698A1 (es) * | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
US20140234298A1 (en) * | 2011-07-06 | 2014-08-21 | Morphosys Ag | Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof |
US20130302274A1 (en) * | 2011-11-25 | 2013-11-14 | Roche Glycart Ag | Combination therapy |
AR090263A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
AR097584A1 (es) * | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
-
2016
- 2016-06-23 CA CA2987716A patent/CA2987716A1/en not_active Abandoned
- 2016-06-23 JP JP2017566659A patent/JP6811733B2/ja active Active
- 2016-06-23 AU AU2016282877A patent/AU2016282877A1/en not_active Abandoned
- 2016-06-23 CR CR20170537A patent/CR20170537A/es unknown
- 2016-06-23 MX MX2017016651A patent/MX2017016651A/es unknown
- 2016-06-23 EP EP16732589.3A patent/EP3313442B1/en active Active
- 2016-06-23 CN CN201680035606.6A patent/CN107847592B/zh active Active
- 2016-06-23 PE PE2017002780A patent/PE20181050A1/es unknown
- 2016-06-23 RU RU2018102575A patent/RU2018102575A/ru not_active Application Discontinuation
- 2016-06-23 US US15/749,251 patent/US20180222985A1/en not_active Abandoned
- 2016-06-23 WO PCT/EP2016/064611 patent/WO2016207312A1/en active Application Filing
- 2016-06-23 KR KR1020187002163A patent/KR20180012873A/ko not_active Application Discontinuation
- 2016-06-23 BR BR112017027614A patent/BR112017027614A2/pt not_active Application Discontinuation
-
2017
- 2017-11-28 ZA ZA2017/08074A patent/ZA201708074B/en unknown
- 2017-12-05 IL IL256135A patent/IL256135A/en unknown
- 2017-12-21 CL CL2017003295A patent/CL2017003295A1/es unknown
-
2018
- 2018-09-21 HK HK18112191.2A patent/HK1252860A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN107847592A (zh) | 2018-03-27 |
IL256135A (en) | 2018-02-28 |
CR20170537A (es) | 2018-02-20 |
RU2018102575A (ru) | 2019-07-25 |
EP3313442B1 (en) | 2019-10-16 |
JP6811733B2 (ja) | 2021-01-13 |
EP3313442A1 (en) | 2018-05-02 |
US20180222985A1 (en) | 2018-08-09 |
CN107847592B (zh) | 2022-01-21 |
HK1252860A1 (zh) | 2019-06-06 |
WO2016207312A1 (en) | 2016-12-29 |
MX2017016651A (es) | 2018-05-14 |
CA2987716A1 (en) | 2016-12-29 |
JP2018525339A (ja) | 2018-09-06 |
AU2016282877A8 (en) | 2018-01-18 |
AU2016282877A1 (en) | 2018-01-04 |
PE20181050A1 (es) | 2018-07-03 |
ZA201708074B (en) | 2018-11-28 |
KR20180012873A (ko) | 2018-02-06 |
BR112017027614A2 (pt) | 2018-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017003295A1 (es) | Anticuerpos contra csf-1r humano para su uso en la inducción de linfocitosis en linfomas o leucemias | |
CL2018002878A1 (es) | Composiciones y anticuerpos anti-tim-3. | |
CL2017002401A1 (es) | Anticuerpos contra icos | |
CL2017000285A1 (es) | Terapia combinada para el tratamiento de un paramixovirus | |
SV2018005684A (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
CY1122721T1 (el) | Αντισωματα που δεσμευουν αχl | |
BR112019005908A2 (pt) | uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres | |
CL2018002012A1 (es) | Derivados de maitansinoide, conjugados de los mismos y métodos de uso. | |
CL2017001361A1 (es) | Anticuerpos heterodiméricos que se unen a cd3 y cd38 | |
AR101697A1 (es) | Terapia de combinación de inmunocitocinas variantes de il-2 dirigidas a tumores y anticuerpos contra pd-l1 humana | |
DOP2016000315A (es) | Anticuerpos monoclonales contra el epítope de her2 y sus métodos de uso | |
DOP2016000153A (es) | Anticuerpos y fragmentos anti-vista | |
CL2017002422A1 (es) | Derivados de maitansinoide, conjugados de los mismos, y métodos de uso. | |
CL2015002562A1 (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
BR112016018891A2 (pt) | anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma | |
BR112016022658A2 (pt) | anticorpos anti-ox40 e métodos de uso | |
BR112015020911A2 (pt) | anticorpo, uso de uma combinação e método de tratamento | |
BR112015032224A2 (pt) | anticorpos anti-fcrh5 | |
BR112016010271A2 (pt) | Anticorpo, composição farmacêutica, método de tratamento, uso de um anticorpo e combinação | |
BR112016026993A2 (pt) | combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer | |
EA201790569A1 (ru) | Антитела и иммуноконъюгаты против cll-1 | |
BR112018067525A2 (pt) | anticorpos tendo especificidade para o btla e seus usos | |
EA201691214A1 (ru) | Антитела к cd33 и иммуноконъюгаты | |
AR104664A1 (es) | Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6) | |
PE20231655A1 (es) | Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso |